Reports
Global Interstitial Cystitis Drugs Market Share, Size, Trends, Growth, Analysis, Forecast: By Drug Class: Ion Channel Blockers, Receptor Antagonists, Enzyme Inhibitors, Protein and Peptide Inhibitors, Others; By Route of Administration; By Key Molecule Type; By Distribution Channel; Regional Analysis; Market Dynamics; Supplier Landscape; 2023-2031
Global Interstitial Cystitis Drugs Market Outlook
The global interstitial cystitis drugs market size reached a value of USD 650 million in 2021. The market is likely to grow at a rate of 7.3% in the forecast period of 2023-2031 to reach a market value of USD 1.33 billion by 2030.
Interstitial Cystitis Insights: Symptoms, Causes, Diagnosis, and Treatment
Interstitial cystitis refers to a chronic urinary disorder that causes inflammation and pain in the urinary bladder or the pelvic region. This disorder is also referred to as bladder pain syndrome or painful bladder syndrome. The pain ranges from mild, moderate to severe, and may even lead to serious complications.
The signs and symptoms of interstitial cystitis vary from patient to patient depending on several factors. The common symptoms include pelvic pain, frequent urination, chronic bladder pain, and difficulty in urination.
The exact cause of interstitial cystitis is unknown but is set to be triggered by various factors. The factors such as defective bladder lining, mast cell abnormalities, the existence of abnormal substances in the urine, associated vascular disease, and other infections or allergies are the potential causes of this disorder.
The diagnosis of interstitial cystitis is done with the help of a pelvic exam, urine test, and other blood and imaging tests. Different diagnostic procedures, such as cystoscopy, biopsy, urine cytology, and potassium sensitivity test are also performed to confirm the presence of this disease.
There is no approved treatment regimen for the management of interstitial cystitis. The healthcare providers prescribe combination therapies for managing the disease symptoms. Different classes of medications and surgical procedures are utilised for controlling the disease progression.
Interstitial cystitis is more prevalent in women as compared to men and most cases are diagnosed at the age of 30 or more.
According to the interstitial cystitis drugs market research report, the market can be categorised into the following segments:
Market Breakup by Drug Class
- Ion Channel Blockers
- Receptor Antagonists
- Enzyme Inhibitors
- Protein and Peptide Inhibitors
- Biological Factor Inhibitors
- Enzyme Activators
- Others
Market Breakup by Route of Administration
- Injection
- Oral
- Topical
- Suppository
- Others
Interstitial Cystitis Drugs Market Breakup by Key Molecule Type
- Small Molecules
- Biologics
- Oligonucleotides
- Others
Market Breakup by Distribution Channel
- Direct Tender
- Retail Sales
- Others
Market Breakup by Region
- North America
- United States of America
- Canada
- Europe
- United Kingdom
- Germany
- France
- Italy
- Others
- Asia Pacific
- China
- Japan
- India
- ASEAN
- Australia
- Others
- Latin America
- Brazil
- Argentina
- Mexico
- Others
- Middle East and Africa
- Saudi Arabia
- United Arab Emirates
- Nigeria
- South Africa
- Others
Interstitial Cystitis Drugs Market Scenario
The growth of the market is driven by the increasing prevalence of interstitial cystitis disease, especially in women. The rising incidence of other associated disorders such as vascular disease or allergies and infections has also been attributed to the growing patient pool. This has facilitated the demand for the diagnostics and therapeutics of interstitial cystitis disease.
The market is further accelerated by the rising healthcare expenditure by public and private firms. Additionally, the increasing disposable incomes and favouring government regulations are bolstering the development of the market.
Improving healthcare awareness and raising awareness among the people regarding the adoption of better and advanced treatment care is also propelling the growth of the market. The key players are effortlessly working on developing new therapeutic interventions, which are expected to aid the market growth during the forecast period.
Interstitial Cystitis Drugs Market Regional Analysis
North America is anticipated to dominate all the regional markets due to the advanced healthcare infrastructure, better diagnostic testing, and growing research and developmental activities in this region. The higher prevalence of interstitial cystitis in North America is also contributing to the increased demand for the market.
Therapeutic Landscape
The treatment of interstitial cystitis depends on the symptoms, severity of the disease and the patient profile. The treatment regimen generally involves a set of different therapeutic interventions to manage the different symptoms.
Oral Medications, Nerve Stimulation Techniques, and Surgical Interventions
The first-line treatment for interstitial cystitis is based on the administration of oral medications. Non-steroidal anti-inflammatory drugs, tricyclic antidepressants, and antihistamines are the standard line of treatment for alleviating acute and chronic pain. The NSAIDs used to relieve pain include ibuprofen or naproxen. Imipramine and amitriptyline are some of the commonly used tricyclic anti-depressants.
Nerve stimulation techniques are also incorporated to relieve pelvic and bladder pain with the conduction and stimulation of nerve impulses and by improving the blood flow to the bladder. The two frequently used nerve stimulation techniques are transcutaneous electrical nerve stimulation and sacral nerve stimulation.
Bladder distention and bladder instillation are therapeutic techniques used to manage the severe symptoms of interstitial cystitis. In bladder distention, the bladder is stretched with water, which may help in pain relaxation. Bladder instillation is the procedure used to administer liquid drug solutions directly to the bladder.
Surgical interventions are usually rarely used and are practised in severe cases of interstitial cystitis. Fulguration, resection, and bladder augmentation are surgical procedures involving the bladder removal or insertion of certain instruments.
In fulguration, an instrument is inserted through the urethra to burn off the ulcers that are present with interstitial cystitis. Resection involves the cutting of any ulcers responsible for causing the disease. Bladder augmentation is the therapeutic procedure of putting an intestinal patch on the bladder to stimulate bladder capacity.
With the high treatment potential, the interstitial cystitis drugs market is likely to witness excellent opportunity for healthcare industries and pharmaceutical companies in extensive therapeutic and diagnostic methods.
Clinical Trials Landscape
A wide array of therapeutic options is available for the management of interstitial cystitis patients, however, there is still a lack of optimal and conservative treatment. Scientists and researchers are continuously studying and analysing the etiology and pathogenesis of the disease to discover a multimodal treatment option. Numerous clinical trials for novel therapeutic products are under process and once approved can assist in the growth of the market.
Clinical Trials and Advent of Emerging Therapies in the Interstitial Cystitis Drugs Market
The intravesical liposomes are the tropical drug carriers that are instilled and attached to the urothelial surface and assist in the restoration of the urothelial barrier function. These liposomes are under clinical testing for assessing their efficacy and tolerability in interstitial cystitis treatment patients. These liposomes consist of sphingomyelin and possess anti-inflammatory effects.
Onabotulinum toxin-filled liposomes are under clinical evaluation in patients suffering from interstitial cystitis. The intravenous injection of onabotulinum has been found beneficial in the palliation of signs and symptoms by inhibiting the bladder’s sensory functions and exhibiting an anti-inflammatory effect.
Alenura, a novel drug candidate, is being discovered by Vaneltix Pharma and Hyloris Pharmaceuticals for treating acute pain in interstitial cystitis. The drug is presently under Phase II clinical trials and has shown the ability to augment the mucous layer of the bladder.
These novel targeted devices and technologies seem to grab the attention of key companies and investors, which will directly influence the development of this sector. This will help enable patient access and growth of the market.
Competitive Landscape
The report gives an in-depth analysis of the key players involved in the interstitial cystitis drugs market, sponsors manufacturing the drugs, and putting them through trials to get FDA approvals. The companies included in the market are as follows:
- Alvogen (CVC Capital Partners)
- Sandoz International GmbH (Novartis AG)
- Sun Pharmaceutical Industries Ltd.
- Accord Healthcare
- Avet Pharmaceuticals Inc. (Heritage Pharmaceuticals Inc.)
- Lannett
- Viatris Inc. (Pfizer Inc.)
- Reckitt Benckiser Group PLC
- VistaPharm, Inc
- Aurobindo Pharma
- Prestige Consumer Healthcare Inc.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
|---|---|
| Base Year | 2022 |
| Historical Period | 2016-2022 |
| Forecast Period | 2023-2031 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Drug Class |
|
| Breakup by Route of Administration |
|
| Breakup by Key Molecule Type |
|
| Breakup by Distribution Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
2 Research Methodology
3 Executive Summary
4 Interstitial Cystitis Overview
4.1 Guidelines and Stages
4.2 Pathophysiology
4.3 Screening and Diagnosis
4.4 Treatment Pathway
5 Patient Profile
5.1 Patient Profile Overview
5.2 Patient Psychology and Emotional Impact Factors
5.3 Risk Assessment and Treatment Success Rate
6 Current Scenario Evaluation and Regulatory Framework
6.1 Emerging Therapies and Clinical Trials
6.2 Patent Landscape
6.2.1 Patent Overview
6.2.1.1 Patent Status and Expiry
6.2.1.2 Timelines from Drug Development to Commercial Launch
6.2.1.3 New Drug Application
6.2.1.3.1 Documentation and Approval Process
6.3 Cost of Treatment
6.4 Regulatory Framework
6.4.1 Regulatory Overview
6.4.1.1 US FDA
6.4.1.2 EU EMA
6.4.1.3 INDIA CDSCO
6.4.1.4 JAPAN PMDA
6.4.1.5 Others
7 Challenges and Unmet Needs
7.1 Treatment Pathway Challenges
7.2 Compliance and Drop-Out Analysis
7.3 Awareness and Prevention Gaps
8 Global Interstitial Cystitis Drugs Market
8.1 Global Interstitial Cystitis Drugs Market Overview
8.2 Global Interstitial Cystitis Drugs Market Analysis
8.2.1 Market Overview
8.2.1.1 Global Interstitial Cystitis Drugs Market Historical Value (2016-2022)
8.2.1.2 Global Interstitial Cystitis Drugs Market Forecast Value (2023-2031)
8.2.2 Global Interstitial Cystitis Drugs Market by Drug Class
8.2.2.1 Market Overview
8.2.2.1.1 Ion Channel Blockers
8.2.2.1.2 Receptor Antagonists
8.2.2.1.3 Enzyme Inhibitors
8.2.2.1.4 Protein and Peptide Inhibitors
8.2.2.1.5 Biological Factor Inhibitors
8.2.2.1.6 Enzyme Activators
8.2.2.1.7 Others
8.2.3 Global Interstitial Cystitis Drugs Market by Route of Administration
8.2.3.1 Market Overview
8.2.3.1.1 Injection
8.2.3.1.2 Oral
8.2.3.1.3 Topical
8.2.3.1.4 Suppository
8.2.3.1.5 Others
8.2.4 Global Interstitial Cystitis Drugs Market by Key Molecule Type
8.2.4.1 Market Overview
8.2.4.1.1 Small Molecules
8.2.4.1.2 Biologics
8.2.4.1.3 Oligonucleotides
8.2.4.1.4 Others
8.2.5 Global Interstitial Cystitis Drugs Market by Distribution Channel
8.2.5.1 Market Overview
8.2.5.1.1 Direct Tender
8.2.5.1.2 Retail Sales
8.2.5.1.3 Others
8.2.6 Global Interstitial Cystitis Drugs Market by Region
8.2.6.1 Market Overview
8.2.6.1.1 North America
8.2.6.1.2 Europe
8.2.6.1.3 Asia Pacific
8.2.6.1.4 Middle East and Africa
8.2.6.1.5 Latin America
9 North America Interstitial Cystitis Drugs Market
9.1 Market Share by Country
9.2 United States of America
9.2.1 Historical Trend (2016-2022)
9.2.2 Forecast Trend (2023-2031)
9.3 Canada
9.3.1 Historical Trend (2016-2022)
9.3.2 Forecast Trend (2023-2031)
10 Europe Interstitial Cystitis Drugs Market
10.1 Market Share by Country
10.2 United Kingdom
10.2.1 Historical Trend (2016-2022)
10.2.2 Forecast Trend (2023-2031)
10.3 Germany
10.3.1 Historical Trend (2016-2022)
10.3.2 Forecast Trend (2023-2031)
10.4 France
10.4.1 Historical Trend (2016-2022)
10.4.2 Forecast Trend (2023-2031)
10.5 Italy
10.5.1 Historical Trend (2016-2022)
10.5.2 Forecast Trend (2023-2031)
10.6 Others
11 Asia Pacific Interstitial Cystitis Drugs Market
11.1 Market Share by Country
11.2 China
11.2.1 Historical Trend (2016-2022)
11.2.2 Forecast Trend (2023-2031)
11.3 Japan
11.3.1 Historical Trend (2016-2022)
11.3.2 Forecast Trend (2023-2031)
11.4 India
11.4.1 Historical Trend (2016-2022)
11.4.2 Forecast Trend (2023-2031)
11.5 ASEAN
11.5.1 Historical Trend (2016-2022)
11.5.2 Forecast Trend (2023-2031)
11.6 Australia
11.6.1 Historical Trend (2016-2022)
11.6.2 Forecast Trend (2023-2031)
11.7 Others
12 Latin America Interstitial Cystitis Drugs Market
12.1 Market Share by Country
12.2 Brazil
12.2.1 Historical Trend (2016-2022)
12.2.2 Forecast Trend (2023-2031)
12.3 Argentina
12.3.1 Historical Trend (2016-2022)
12.3.2 Forecast Trend (2023-2031)
12.4 Mexico
12.4.1 Historical Trend (2016-2022)
12.4.2 Forecast Trend (2023-2031)
12.5 Others
13 Middle East and Africa Interstitial Cystitis Drugs Market
13.1 Market Share by Country
13.2 Saudi Arabia
13.2.1 Historical Trend (2016-2022)
13.2.2 Forecast Trend (2023-2031)
13.3 United Arab Emirates
13.3.1 Historical Trend (2016-2022)
13.3.2 Forecast Trend (2023-2031)
13.4 Nigeria
13.4.1 Historical Trend (2016-2022)
13.4.2 Forecast Trend (2023-2031)
13.5 South Africa
13.5.1 Historical Trend (2016-2022)
13.5.2 Forecast Trend (2023-2031)
13.6 Others
14 Global Interstitial Cystitis Drugs Market Dynamics
14.1 Market Drivers and Constraints
14.2 SWOT Analysis
14.3 Porter’s Five Forces Model
14.4 Key Demand Indicators
14.5 Key Price Indicators
14.6 Industry Events, Initiatives & Trends
14.7 Value Chain Analysis
15 Supplier Landscape
15.1 Alvogen (CVC Capital Partners)
15.1.1 Company Overview
15.1.2 Product Portfolio
15.1.3 Demographic Reach and Achievements
15.1.4 Mergers and Acquisitions
15.1.5 Certifications
15.2 Sandoz International GmbH (Novartis AG)
15.2.1 Company Overview
15.2.2 Product Portfolio
15.2.3 Demographic Reach and Achievements
15.2.4 Mergers and Acquisitions
15.2.5 Certifications
15.3 Sun Pharmaceutical Industries Ltd.
15.3.1 Company Overview
15.3.2 Product Portfolio
15.3.3 Demographic Reach and Achievements
15.3.4 Mergers and Acquisitions
15.3.5 Certifications
15.4 Accord Healthcare
15.4.1 Company Overview
15.4.2 Product Portfolio
15.4.3 Demographic Reach and Achievements
15.4.4 Mergers and Acquisitions
15.4.5 Certifications
15.5 Avet Pharmaceuticals Inc. (Heritage Pharmaceuticals Inc.)
15.5.1 Company Overview
15.5.2 Product Portfolio
15.5.3 Demographic Reach and Achievements
15.5.4 Mergers and Acquisitions
15.5.5 Certifications
15.6 Lannett
15.6.1 Company Overview
15.6.2 Product Portfolio
15.6.3 Demographic Reach and Achievements
15.6.4 Mergers and Acquisitions
15.6.5 Certifications
15.7 Viatris Inc. (Pfizer Inc.)
15.7.1 Company Overview
15.7.2 Product Portfolio
15.7.3 Demographic Reach and Achievements
15.7.4 Mergers and Acquisitions
15.7.5 Certifications
15.8 Reckitt Benckiser Group PLC
15.8.1 Company Overview
15.8.2 Product Portfolio
15.8.3 Demographic Reach and Achievements
15.8.4 Mergers and Acquisitions
15.8.5 Certifications
15.9 VistaPharm, Inc
15.9.1 Company Overview
15.9.2 Product Portfolio
15.9.3 Demographic Reach and Achievements
15.9.4 Mergers and Acquisitions
15.9.5 Certifications
15.10 Aurobindo Pharma
15.10.1 Company Overview
15.10.2 Product Portfolio
15.10.3 Demographic Reach and Achievements
15.10.4 Mergers and Acquisitions
15.10.5 Certifications
15.11 Prestige Consumer Healthcare Inc.
15.11.1 Company Overview
15.11.2 Product Portfolio
15.11.3 Demographic Reach and Achievements
15.11.4 Mergers and Acquisitions
15.11.5 Certifications
16 Global Interstitial Cystitis Drugs Market- Distribution Model (Additional Insight)
16.1 Overview
16.2 Potential Distributors
16.3 Key Parameters for Distribution Partner Assessment
17 Payment Methods (Additional Insight)
17.1 Government Funded
17.2 Private Insurance
17.3 Out-of-Pocket
*Additional insights provided are customizable as per client requirements.
Key Questions Answered in the Report
The growth of the market is primarily driven by the rising prevalence of interstitial cystitis, growing cases of urinary tract infections, rising adoption of advanced healthcare, and increasing research and developmental activities.
Based on the drug class, the market is categorised into ion channel blockers, receptor antagonists, enzyme inhibitors, protein and peptide inhibitors, biological factor inhibitors, and enzyme activators, among others.
Based on the route of administration, the market is segmented into injection, oral, topical, and suppository, among others.
Based on the key molecule type, the market is bifurcated into small molecules, biologics, and oligonucleotides, among others.
Based on the distribution channel, the market is divided into direct tender and retail sales, among others.
The different regions in the market are North America, Europe, Asia Pacific, Latin America, the Middle East and Africa. North America is anticipated to hold the largest share of the global market during the forecast period.
The key companies involved in the market are Alvogen (CVC Capital Partners), Sandoz International GmbH (Novartis AG), Sun Pharmaceutical Industries Ltd., Accord Healthcare, Avet Pharmaceuticals Inc. (Heritage Pharmaceuticals Inc.), Lannett, Viatris Inc. (Pfizer Inc.), Reckitt Benckiser Group PLC, VistaPharm, Inc, Aurobindo Pharma, and Prestige Consumer Healthcare Inc., among others.
Purchase Options
Call us on
Purchase Full Report
Mini Report
$3499
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next UpdateSingle User License
$5999-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next Update
Five User License
$7999-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$9999-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Contact AnalystAny Question? Speak With An Analyst
Request SampleView A Sample
Request CustomisationDid You Miss Anything, Ask Now
Why Expert Market Research?Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
Similar Reports
NEWSLETTER